Парацетамол-УБФ

Quick links

Choose a section

Quick links to important sections

Advertisements

Парацетамол-УБФ

Selected form

Advertisements
Advertisements

Overview of Парацетамол-УБФ

What is Paracetamol-UBF?

Property Description
Active ingredient Paracetamol (Acetaminophen)
Form Tablets (for oral administration)
Pharmacological class Non-narcotic Analgesic and Antipyretic
Common use Symptomatic relief of pain and fever
Origin Synthetic (Para-aminophenol derivative)

What is Paracetamol-UBF and What Class Does it Belong To?

Paracetamol-UBF is a synthetic medicinal product, manufactured by Uralbiopharm, that is classified as a non-narcotic analgesic and antipyretic. The medication’s active ingredient is the well-known substance Paracetamol, internationally recognized as Acetaminophen (INN). Acetaminophen is a widely used over-the-counter pain reliever and fever reducer. As a single-ingredient drug, or monopreparation, it is widely available for over-the-counter (OTC) purchase.


Composition and Dosage Form: What is its Origin?

The composition of Paracetamol-UBF is centered on the chemically synthesized active substance, Paracetamol. Its synthetic origin ensures high purity and consistent formulation. The drug is typically supplied for oral administration in the dosage form of tablets, suitable for adults and older children. This solid form includes the precise amount of Paracetamol and standard excipients that constitute the solid oral formulation base.


General Purpose: What Does it Help to Relieve?

The general purpose of Paracetamol-UBF is to provide symptomatic relief by reducing pain and lowering elevated body temperature. It achieves this by acting primarily on the Central Nervous System (CNS), where it affects the body's perception of pain and helps to reset the thermoregulation center in the hypothalamus. Paracetamol is effective for treating acute pain and fever. While highly effective as an analgesic and antipyretic, its anti-inflammatory effect in peripheral tissues is considered minimal, a characteristic that differentiates it from other pain relievers.

Advertisements

What side effects are possible with Парацетамол-УБФ?

Possible Side Effects and Safety Information

The official safety profile for Paracetamol-UBF (Paracetamol/Acetaminophen) is fundamentally defined by the potential for hepatotoxicity (liver damage), which is the primary and most significant adverse event documented in regulatory labeling. This risk is critically linked to exceeding the maximum recommended daily dose, leading to the designation of acute liver failure as a serious adverse reaction.

The adverse reactions are categorized by frequency and system-organ class based on official regulatory data:

Classification System-Organ Class Involved Examples of Adverse Reactions
Rare Blood and lymphatic system disorders Thrombocytopenia, agranulocytosis
Very Rare Skin and subcutaneous tissue disorders Severe Cutaneous Adverse Reactions (SCARs), including SJS and TEN
Not Known Immune system disorders Anaphylactic shock, angioedema

Serious adverse reactions also include rare but potentially fatal events like the severe skin conditions (SCARs) and anaphylaxis. Population-specific safety considerations are explicitly stated in the official labels. The medication is generally contraindicated in cases of severe hepatocellular insufficiency. Furthermore, patients with chronic alcohol abuse or pre-existing hepatic impairment are identified as having a significantly increased risk of hepatotoxicity. Official labeling strictly prohibits taking this medication with any other product containing Paracetamol to prevent accidental overdose and subsequent liver damage.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Overdose scope

Feature Official Regulatory Statements (Paracetamol / Acetaminophen)
Documented overdose presentations Initial manifestations (within 24 hours) may include nausea, vomiting, pallor, anorexia, and abdominal pain. Symptoms may be minimal or non-specific at first.
Physiological systems affected Hepatic system (leading to hepatic failure/necrosis), Renal system (leading to acute tubular necrosis/acute renal failure), and Central Nervous System (leading to encephalopathy).
Dose-related or exposure-related factors The hazard is greater in individuals with existing non-cirrhotic alcoholic liver disease, chronic malnutrition, or those taking enzyme-inducing drugs.
Emergency-response statements Immediate medical management is required. The patient should be referred to a hospital urgently for immediate medical attention. Contacting the Poison Control Center is mandated.
When immediate medical help is required Immediate medical management is required in the event of overdose, even if symptoms are not present.

Key Overdose Classifications

Classification Aspect Official Regulatory Statement
Severity classification The outcome of untreated overdose is classified as a potentially fatal event, specifically due to irreversible hepatic failure.
Overdose-context constraints The efficacy of the antidote, N-acetylcysteine (NAC), is time-dependent, with maximal protective effect achieved when administered within 8 hours post-ingestion.

Official Overdose Statements

  • Hepatic failure is documented as the most severe, life-threatening consequence of overdose.
  • The administration of the antidote, N-acetylcysteine (NAC), is required to prevent or lessen the severe hepatic injury.
  • Activated charcoal should be considered as a supportive measure only if the overdose has occurred within 1 hour of presentation.
  • Assessment requires monitoring of plasma paracetamol concentration and specific laboratory tests to check for abnormal liver function and coagulation defects.

Connection to the overall overdose profile: The regulatory profile defines overdose primarily through the time-sensitive risk of hepatic toxicity, establishing that immediate medical management is required, even in the absence of symptoms, due to the progressive nature of the injury. This urgent requirement is underscored by the documented efficacy window for the antidote, N-acetylcysteine, and the necessity for prompt laboratory monitoring to assess the risk and guide treatment initiation. The documented manifestations transition from initial non-specific signs to severe complications, dictating a non-negotiable help-seeking action to mitigate the potential for fatal outcomes.

Advertisements

Therapeutic Uses of Парацетамол-УБФ

What Парацетамол-УБФ Treats: Main Uses and Benefits

The primary role of Парацетамол-УБФ is to provide effective symptomatic relief across key domains of discomfort, helping to ease the overall symptom burden. The medication is commonly used to help with symptoms related to physical discomfort and systemic imbalance, namely pain and fever.

The medication is generally applied in situations involving acute or episodic manifestations and is relevant for easing common discomforts. These indications often include tension headaches, dental pain, muscular aches, and menstrual cramps, as well as the elevated body temperature and body aches associated with common colds and influenza. This support helps patients cope more steadily with symptom fluctuations.

“This widely used medication is generally considered relevant for managing mild to moderate acute pain and is a commonly used option for antipyresis across various patient groups.”


Quick Fact: Relief for Pain and Fever

Парацетамол-УБФ is a key option in scenarios where short-term symptomatic assistance is needed. Managing the fever and aches may assist with easing functional strain related to symptoms, contributing to better day-to-day comfort. It supports patients during episodes of heightened discomfort and is considered a preferred choice for necessary relief in sensitive patient contexts, including pregnant individuals and breastfeeding mothers.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

Парацетамол-УБФ (Paracetamol-UBF) is subject to strict regulatory rules detailing who can and cannot use the medicine, based on health status and age.

Eligibility Group Regulatory Status
General Adult Population Allowed
Children 10–15 Years Allowed (with specific pediatric dosing)
Children Under 10 Years Not recommended (use alternative formulations)
Hypersensitivity Contraindicated
Severe Hepatic Failure Contraindicated

Use of this medicine is contraindicated for individuals with known hypersensitivity to paracetamol or any excipients, and those with severe hepatocellular insufficiency or severe hepatic failure. Use must be avoided by patients taking other paracetamol-containing products to prevent severe liver damage.

Special Considerations and Restrictions

Use is allowed only with caution and often requires a reduced dose, an extended dosing interval (e.g., 6 hours), or a lower maximum daily dose in patients with: severe renal insufficiency ( creatinine clearance leq 30 mL/min), chronic alcoholism, chronic malnutrition, dehydration, and non-severe hepatic insufficiency (including Gilbert's syndrome).

Pregnancy and Lactation

Paracetamol is allowed during pregnancy if clinically necessary. It must be used at the lowest effective dose, for the shortest duration, and as infrequently as possible. It is allowed during lactation at therapeutic doses.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interactions for Paracetamol-UBF (Acetaminophen) based on government regulatory sources.

Classification Interacting Agents / Constraint Regulatory Basis
Do Not Combine Other products containing Paracetamol (Acetaminophen); Chronic excessive alcohol consumption. Risk of acute liver damage/failure.
Pharmacodynamic Risk Oral Anticoagulants (Coumarins, e.g., Warfarin); Flucloxacillin; Zidovudine. Risk of enhanced bleeding (with prolonged regular use); Risk of high anion gap metabolic acidosis; Risk of neutropenia.
Exposure Modifiers Liver Enzyme Inducers; Probenecid; Metoclopramide / Domperidone; Cholestyramine. Increased toxicity risk or reduced efficacy; Decreased clearance/increased plasma levels; Increased speed of absorption; Reduced absorption.

Interaction-Specific Restrictions and Cautions:

  • Other Medicines: The co-administration of other Paracetamol-containing products is strictly restricted to avoid exceeding the maximum daily dose.
  • Alcohol: Regular, chronic consumption of alcohol is specifically warned against in regulatory documentation due to the heightened risk of severe hepatotoxicity.
  • Timing: The absorption-reducing agent Cholestyramine requires a mandated time separation: Paracetamol-UBF should be administered at least one hour before this substance.
  • Population Note: The interaction-related risk of severe liver damage is greater in individuals with Chronic Alcoholism or Non-Cirrhotic Alcoholic Liver Disease, as noted in official prescribing information.

The regulatory profile is structured around identifying agents that modify the drug's metabolic clearance, such as enzyme inducers that increase toxicity risk, and those that introduce Pharmacodynamic Risk, like the increased bleeding potential documented with prolonged regular use of oral anticoagulants. This classification establishes strict limitations on certain combinations to maintain safety standards.

Advertisements

Mechanism of Action

Targeting Central Prostaglandin Synthesis and Thermoregulation

The drug's primary mechanism involves the selective inhibition of cyclooxygenase (COX) enzymes specifically within the Central Nervous System (CNS), thereby suppressing the synthesis of prostaglandins, which act as key signals in thermoregulation and nociception. This action directly targets the hypothalamic thermoregulation center, leading to a reset of the body's temperature set-point which then initiates mechanisms like peripheral vasodilation and sweating resulting in increased heat dissipation.

Modulation of Central Nociceptive Pathways

The drug also exerts an effect through its active metabolite, AM404, which modulates spinal nociceptive signal transmission by interacting with receptors like TRPV1 and influencing the endocannabinoid system. This activity strengthens the body’s descending inhibitory pathways, which are systems responsible for inhibiting the transmission of nociceptive input at the spinal level.

Mechanistic Limitation in Peripheral Tissues

A characteristic limitation of this mechanism is its minimal effect on peripheral inflammation, as the high concentration of peroxides found in tissues where high concentrations of hydroperoxides are present overrides the drug’s inhibitory action on peripheral COX enzymes. This constraint confines the drug's physiological influence mainly to central thermoregulatory and nociceptive systems.

Advertisements

Dosage and Administration Information

The use of Парацетамол-УБФ is defined by official administration protocols that establish strict parameters for dose, frequency, and duration. As an oral tablet, its administration route is oral, although the active substance is also approved for intravenous and rectal delivery in other forms. The core principle of its administration is adherence to limits designed for intermittent, short-term application.

For adults weighing 50 kg or more, the standard single dose is 500 mg to 1,000 mg. Usage is governed by a minimum required interval of 4 hours between doses of immediate-release formulations. Crucially, the total intake from all sources must not exceed the 4,000 mg (4 g) maximum daily dose. The tablets may be taken with or without food, and they should be swallowed whole with water for proper ingestion. Use is generally intended to be short-term, such as 10 days for pain.

Dose modifications are officially mandated for specific patient groups to align with physiological factors. Pediatric administration is determined by body weight, calculated at 10 mg/kg to 15 mg/kg per dose. Additionally, an adjustment (dose reduction or interval extension) is required for patients with documented severe renal or hepatic impairment. These official instructions establish the complete procedural framework for the correct, label-aligned use of the medicine.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Парацетамол-УБФ

Evidence for Symptomatic Relief of Acute Pain

Paracetamol-UBF was studied for physical discomfort, such as mild to moderate acute pain, in research exploring how symptoms change over time. The evidence for this indication includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were conducted during research exploring short-term symptom changes in patient-reported experiences, and research explored changes in outcomes related to physical discomfort.

Research examined pain intensity using standardized patient scales and studies monitored how participants reported their perceived discomfort over short, defined time intervals. Findings describe patterns observed in the studies where participants tracked their symptom changes, helping to contextualize how patients reported their experience of short-term changes. However, follow-up durations were limited in many of these trials, and comparative evidence is lacking for some specialized forms of acute pain.


Evidence for Antipyresis (Fever Reduction)

Evidence for Antipyresis (Fever Reduction)

The use of Paracetamol-UBF for antipyresis, or when research examined temporary physiological imbalance, was studied for febrile conditions where temperature may vary in intensity. Research examined outcomes related to systemic or functional imbalance, specifically changes in core body temperature and the duration of fever. Studies report how symptoms evolved in the observed populations; data show patterns related to temperature changes observed in some studies over defined time intervals. This evidence contributes to the broader evidence landscape related to examining temporary physiological imbalance.

Certainty remains low when directly comparing Paracetamol-UBF to other fever-reducing medicines for specific outcomes in some young children. Furthermore, studies generally focus on temporary changes, meaning long-term outcomes are not fully established regarding the overall course of a febrile illness.


Studies in Special Populations and Research Gaps

Paracetamol-UBF was studied for various patient groups beyond the general adult population, including pediatric patients. For pregnant and breastfeeding individuals, observational settings evaluating daily-life functioning are the main source of information. These large-scale studies tracked medicine usage patterns and findings indicate specific outcomes was observed in some studies. Because controlled trials are rare in these sensitive groups, data for certain groups remain insufficient for high-certainty conclusions.

Research has also explored its use in specific long-term conditions like osteoarthritis of the hip and knee. However, evidence quality varies across studies, and findings were mixed regarding the magnitude of change. Sample sizes were modest in some specific comparative trials, meaning that subgroup findings are uncertain in distinguishing between Paracetamol-UBF and other factors being examined in the studies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Парацетамол-УБФ (FAQ)

Q: What is the difference between Paracetamol-UBF and regular Paracetamol?

A: Paracetamol-UBF is a commercial brand name for a medicine that contains the active ingredient Paracetamol, which is internationally recognized as Acetaminophen. Official sources indicate that in terms of the primary therapeutic component, it is identical to other medicines containing this substance. The 'UBF' designation typically refers to the specific manufacturer or formulation type.

Q: Is it possible to take Paracetamol-UBF during pregnancy?

A: Official regulatory documents state that Paracetamol is allowed for use during pregnancy if a medical professional deems it clinically necessary. Regulatory documents describe that use is limited to the lowest effective dose, shortest duration, and least frequent application possible.

Q: Can Paracetamol-UBF be taken on an empty stomach?

A: According to the official prescribing information, Paracetamol-UBF tablets may be taken with or without food. Official prescribing information notes that administration with food may lead to a slight delay in the rate of absorption of the active substance.

Q: Does it interact with popular supplements (vitamins)?

A: Regulatory documentation focuses mainly on interactions with prescribed medications and alcohol. Official sources note that data are often insufficient to fully assess the safety of Paracetamol in combination with many vitamins and general supplements.

Q: Can Paracetamol-UBF be taken if I am taking other cold medicines?

A: Regulatory agencies strictly prohibit taking Paracetamol-UBF concurrently with any other product that contains Paracetamol (Acetaminophen). This restriction is in place because co-administration significantly increases the risk of exceeding the maximum dose, which can lead to severe liver damage.

Q: Does the leaflet contain information on the ability to drive a car?

A: Official product information generally states that when used at recommended doses, Paracetamol-UBF typically does not affect the ability to drive or operate machinery. However, if a patient experiences any rare adverse effects, such as dizziness or impaired vision, the regulatory profile advises caution if such effects are experienced.

Q: What are the registered dosage forms of Paracetamol-UBF (tablets, syrup, etc.)?

A: While the active ingredient, Paracetamol, is available in various registered forms worldwide, including oral solutions, injections, and suppositories, the specific brand Paracetamol-UBF is supplied in the dosage form of oral tablets.

Q: How long does it take for Paracetamol-UBF to start working?

A: According to pharmacokinetics data in official documents, the therapeutic effect can often be noticed approximately 30 to 60 minutes after oral administration. The medicine typically reaches its maximum concentration in the blood plasma within 30 to 240 minutes.

Q: How long can Paracetamol-UBF be taken?

A: Official regulatory guidelines state that for the self-treatment of pain, the medicine is typically used for no more than 10 days, and for fever, no more than 3 days, without consulting a healthcare professional. Use beyond these timeframes is typically stated in the regulatory profile as requiring medical monitoring.

Q: How quickly is Paracetamol-UBF eliminated from the body?

A: Pharmacokinetic data from official documents indicate that the elimination half-life—the time required for the concentration of the active substance in the blood to decrease by half—is generally between 1.9 and 2.5 hours in adults with normal liver function.

Q: Does Paracetamol-UBF have a cumulative effect in the body?

A: Paracetamol-UBF is typically metabolized quickly by the liver and eliminated by the kidneys, so it does not have a cumulative effect in the usual sense. However, official warnings caution that repeat administration before the minimum required interval has passed can lead to the accumulation of a toxic metabolite, increasing the risk of hepatotoxicity.

Q: How long does the temperature-lowering effect of Paracetamol-UBF last?

A: Official clinical data suggests that the antipyretic (fever-reducing) effect typically lasts for approximately 4 to 6 hours after a recommended dose. This duration generally aligns with the minimum time interval advised between doses of the medicine.

Q: Does Paracetamol-UBF cause drowsiness?

A: According to official adverse event listings, drowsiness (somnolence) is not included among the frequent or common side effects when the medicine is used at therapeutic doses. Rare side effects related to the nervous system, such as dizziness, have been reported.

Q: Is Paracetamol-UBF an original drug or a generic?

A: The active substance, Paracetamol, is no longer protected by patent and is classified as a generic compound. Paracetamol-UBF is considered a branded generic or equivalent drug, meaning it contains the same active ingredient as the original patented medicine.

Q: Can Paracetamol-UBF help with muscle pain after a workout?

A: Official indications state that this medicine is used for the symptomatic relief of general or moderate acute pain. Muscle pain experienced after physical exertion falls under the scope of its analgesic (pain-relieving) indications.

Q: Can Paracetamol-UBF cause addiction?

A: Official regulatory warnings clarify that Paracetamol-UBF is not classified as a controlled substance, and official regulatory warnings clarify that it is not associated with physical dependence or addiction.

Q: Does Paracetamol-UBF affect blood or urine tests?

A: Official labeling includes warnings that Paracetamol may affect the results of certain laboratory tests. For example, it has been described as potentially causing false-positive results when testing for uric acid and false-negative results when testing for blood glucose.

Q: Is Paracetamol-UBF considered safe for long-term use?

A: Regulatory sources state that long-term regular use of the medicine is generally not recommended without medical supervision. Chronic application can increase the risk of developing serious side effects, most notably hepatotoxicity (liver damage).

Q: What do official sources say about Paracetamol-UBF overdose?

A: Official regulatory warnings clearly state that an overdose of Paracetamol is a medical emergency that can lead to severe liver damage and death. The risk of liver damage is present even when only slightly exceeding the maximum recommended daily dose.

Q: What is known about the safety of Paracetamol-UBF for elderly people?

A: While official documents do not mandate automatic dose adjustments based on age alone, some regulatory guidelines describe reduced maximum daily doses to mitigate potential risks for older patients. This is often related to the possibility of reduced liver reserves.

Advertisements

How should Парацетамол-УБФ be stored and disposed of?

How to Store and Dispose of Парацетамол-УБФ?

The storage of Paracetamol-UBF tablets must strictly adhere to regulatory guidelines to ensure product stability and safety. The official labeled requirements address temperature control, environmental protection, and accessibility.


Storage Conditions

Requirement Official Regulatory Mandate
Temperature Store at temperatures not exceeding 30 C (86 F).
Environment Must be stored in a dry place and protected from light.
Container Keep in the original package and ensure the container is tightly closed.
Safety Must be stored out of the sight and reach of children.

Disposal Requirements

Disposal of unused or expired tablets should be done via a drug take-back program. If a take-back option is unavailable, the official guidance is to mix the medicine with an undesirable substance (e.g., dirt or coffee grounds) and place it in a sealed container before discarding in household trash. Disposal via wastewater is generally restricted.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Парацетамол-УБФ found in:

A-Z Index: